Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 2 (2005), Issue 12 (December)

1. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
   Cancer Res, 65(23): 11118-28. [Abstract] [Full-text]
2. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
   Cancer Res, 65(23): 11018-25. [Abstract] [Full-text]
3. Control of recombinant monoclonal antibody effector functions by fc N-glycan remodeling in vitro.
   Biotechnol Prog, 21(6): 1644-52. [Abstract] [Full-text]
4. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.
   Proc Natl Acad Sci U S A, 102(50): 17987-92. [Abstract] [Full-text]
5. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
   Cancer Sci, 97(1): 72-9. [Abstract] [Full-text]
6. Towards a therapeutic breast cancer vaccine: the next steps.
   Expert Rev Vaccines, 4(6): 831-41. [Abstract] [Full-text]
7. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
   Int J Cancer, 118(5): 1126-34. [Abstract] [Full-text]
8. Mechanisms of trastuzumab resistance and their clinical implications.
   Ann N Y Acad Sci, 1059: 70-5. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.